Okayama A, Maruyama T, Tachibana N, Hayashi K, Kitamura T, Mueller N, Tsubouchi H
Second Department of Internal Medicine, Miyazaki Medical School.
Jpn J Cancer Res. 1995 Jan;86(1):1-4. doi: 10.1111/j.1349-7006.1995.tb02979.x.
The progression from chronic hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC) has been reported. We evaluated whether co-infection with the human T-lymphotropic virus type I (HTLV-I) might be associated with this transition in a cross-sectional analysis of 127 patients with HCV-chronic hepatitis (mean age = 51.7) and 43 patients with HCV-associated HCC (mean age = 62.4); the seroprevalence of anti-HTLV-I was 9.5% and 30.2%, respectively. For subjects 50 years or older, the seroprevalence of anti-HTLV-I in HCC patients was 13/41 (31.7%) which was significantly higher than that in chronic hepatitis patients (6/82, 7.3%) (P = 0.001). The relative risk (RR) of association was 12.8 (P = 0.0004) among the males, however, no association was evident among the females, RR = 1.3 (P = 0.80). The increased prevalence of HTLV-I positivity among the HCC cases could not be attributed to a higher rate of prior transfusion. These data suggest that co-infection with HTLV-I may contribute to the development of HCC among patients with HCV-induced chronic liver diseases in a highly HTLV-I-endemic area.
据报道,慢性丙型肝炎病毒(HCV)感染可进展为肝细胞癌(HCC)。我们在一项横断面分析中评估了人类I型嗜T淋巴细胞病毒(HTLV-I)合并感染是否可能与这种转变相关,该分析纳入了127例HCV慢性肝炎患者(平均年龄 = 51.7岁)和43例HCV相关HCC患者(平均年龄 = 62.4岁);抗HTLV-I的血清阳性率分别为9.5%和30.2%。对于50岁及以上的受试者,HCC患者中抗HTLV-I的血清阳性率为13/41(31.7%),显著高于慢性肝炎患者(6/82,7.3%)(P = 0.001)。男性中的关联相对风险(RR)为12.8(P = 0.0004),然而,女性中未发现明显关联,RR = 1.3(P = 0.80)。HCC病例中HTLV-I阳性率的增加不能归因于既往输血率较高。这些数据表明,在HTLV-I高流行地区,HTLV-I合并感染可能促进HCV诱导的慢性肝病患者发生HCC。